EG Labo Tamsulosine EG LP 0,4 mg

Tamsulosine EG LP is a generic prescription medication used primarily for the treatment of symptoms associated with Benign Prostatic Hyperplasia (BPH). It belongs to a class of drugs known as alpha-1 blockers, which work by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. This specific presentation consists of 30 prolonged-release capsules (0.4 mg).

The product is marketed by EG Labo (Laboratoires Eurogenerics), a major player in the French generic medicine market. Founded in 1996 and headquartered in Issy-les-Moulineaux, France, EG Labo provides one of the broadest ranges of generic drugs in the country. While the company is French-based and focuses heavily on the French healthcare system, it operates as a key subsidiary of a much larger international pharmaceutical entity.

EG Labo is a subsidiary of the STADA Group, a leading German pharmaceutical company headquartered in Bad Vilbel. STADA itself is owned by the private equity firms Bain Capital and Cinven, following a major acquisition in 2017. This ownership structure allows EG Labo to leverage global manufacturing and research resources while maintaining its strong local presence in France.